{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 60,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The slide outlines a standard oncology dose-escalation study design (3+3 or similar) followed by expansion cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/37",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Dose escalation steps (0.16, 0.32, 0.51, 0.82, DLX) leading to MTD/RP2D expansion into two cohorts (MYD88MT and MYD88WT).",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59b2c19a-ae73-46e9-a7db-801083e592cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "MTD: Maximum Tolerated Dose. RP2D: Recommended Phase 2 Dose. ORR: Overall Response Rate",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6048e692-910d-4c51-8bb3-52b75add18f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "table",
      "text": "Key Objectives for Phase 1a and 1b covering Primary, Secondary, and Exploratory goals.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7f57eda-01d8-4a13-a2a2-99ffb093bf22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-413: Phase 1, Multicenter, Dose-Escalation and Expansion Trials to Evaluate KT-413 in Patients with R/R DLBCL",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54bbca21-58f2-4c2b-8d6a-7234cf2a4094",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "129d513b-4be7-4cfe-bcc6-8a37b5493218",
      "evidence": "Standard dose-escalation and expansion cohort structure",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}